Section Arrow
LBRX.NASDAQ
- LB Pharmaceuticals Inc
Quotes are at least 15-min delayed:2026/01/02 01:35 EST
Regular Hours
Last
 22.26
+0.76 (+3.53%)
Day High 
23.1075 
Prev. Close
21.5 
1-M High
23.15 
Volume 
262.67K 
Bid
20
Ask
36.03
Day Low
21.2801 
Open
21.58 
1-M Low
16.32 
Market Cap 
543.93M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 21.08 
20-SMA 20.59 
50-SMA 17.84 
52-W High 23.15 
52-W Low 13.36 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.74/--
Enterprise Value
547.15M
Balance Sheet
Book Value Per Share
12.26
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
MREOMereo BioPharma Group plc0.4167+0.0462+12.47%-- 
OTLKOutlook Therapeutics1.58-0.285-15.28%0.58PE
VNDAVanda Pharmaceuticals8.82+1.79+25.46%126.25PE
SLSSELLAS Life Sciences Group3.77+0.46+13.90%-- 
FBLGFibroBiologics0.2249-0.017-7.03%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broadtherapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.